Clinical trials
Adenocarcinoma clinical trials
Below are recruiting adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 995 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06761846RecruitingPhase 2
Immunotherapy and chemo after stomach cancer surgery
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from coming back. You may qualify if you had D2 surgery and your tumor tested positive for PD-L1.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07353684RecruitingPhase 2
Adebrelimab plus apatinib with chemo for gastric cancer
This trial tests a combination of two targeted drugs (adebrelimab and apatinib) with standard chemotherapy (SOX regimen) before surgery for gastric cancer that cannot be removed right away. The goal is to shrink the tumor enough to make surgery possible.
Beijing, Beijing MunicipalityAges 18–75 - NCT07347314RecruitingPhase 2
Enfortumab vedotin for advanced small bowel adenocarcinoma
This trial tests a drug called enfortumab vedotin for people with advanced small bowel adenocarcinoma that has worsened after platinum-based chemotherapy. The goal is to see if it can shrink tumors or slow the disease.
FukuokaAges 18 years+ - NCT07340151Recruiting
Surgery for limited liver or lung pancreatic cancer spread
This trial tests whether removing or ablating limited liver or lung tumors from pancreatic cancer that has not spread elsewhere, along with a specific chemotherapy (NALIRIFOX), can help patients. It is for people who have not had any previous cancer treatment.
San Antonio, TexasAges Any age - NCT05170503RecruitingPhase 2
Immunotherapy plus chemo before surgery for junction stomach cancers
This Phase 2 study tests giving immunotherapy together with chemotherapy before surgery for certain “locally advanced” cancers at the esophagus-stomach junction. It may help shrink the tumor and improve outcomes by treating the cancer earlier with both immune and chemotherapy approaches.
Guangzhou, GuangdongAges 18–75 - NCT05960955RecruitingPhase 2
Testing immunotherapy plus chemo around the time of gastric surgery
This study tests whether adding cadonilimab (and possibly AK117) to chemotherapy can improve outcomes for people with resectable stomach or stomach–esophagus cancer. It aims to see if this combination works better than chemotherapy alone, while still being safe around surgery.
TianjinAges 18–75 - NCT06747845RecruitingPhase 2
Maintenance therapy for stable metastatic pancreatic cancer
This trial tests a combination of two drugs, niraparib and ipilimumab, as a maintenance treatment for people with metastatic pancreatic cancer that has not grown after initial chemotherapy. The goal is to see if this can help keep the cancer stable longer.
Boston, MassachusettsAges 18 years+ - NCT06059495RecruitingPhase 2
Watch-and-wait with dostarlimab for MSI-H stomach cancer
This trial is testing a watch-and-wait approach using the immunotherapy drug dostarlimab for people with a specific type of stomach cancer (dMMR/MSI-H) that hasn't spread. The goal is to see if the drug can eliminate the need for surgery or other treatments.
LilleAges 18–75 - NCT07462923RecruitingPhase 1
A study of HS-20093 for advanced stomach or gastroesophageal cancer
This trial tests a new drug, HS-20093, in people with advanced stomach or gastroesophageal junction cancer that has not responded to other treatments. The goal is to see if it can help shrink or slow the growth of the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05624918RecruitingPhase 2
Testing a tumor-treatment device plus chemotherapy for pancreatic cancer
This trial studies NovoTTF-200T(P), a portable treatment device, combined with standard chemotherapy (gemcitabine and nab-paclitaxel) for people with resectable pancreatic adenocarcinoma. It aims to improve treatment results by trying this combination before surgery.
Columbus, OhioAges 18 years+ - NCT07569068RecruitingPhase 2
Combination Cancer Drugs Before Surgery for Stomach Cancer
This trial tests whether giving immunotherapy and chemotherapy drugs before surgery can help treat stomach cancer that has a specific protein marker (claudin 18.2). The goal is to shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
Shanghai, Huangpu DistrictAges 18 years+ - NCT05753306RecruitingPhase 2
Robot surgery plus heated chemo for limited spread stomach cancer
This study tests a “robot-assisted” surgery to remove stomach cancer in the belly lining (peritoneum) along with heated chemotherapy placed inside the abdomen. It’s for people whose cancer has spread only in the peritoneum, aiming to control disease when there’s a good chance of removing it all.
Rochester, MinnesotaAges 18–80 - NCT07303465RecruitingPhase 2
Testing a new drug for KRAS G12D pancreatic cancer
This trial tests a new experimental drug, RNK08954, for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and can help shrink or slow the cancer.
NanjingAges 18–75 - NCT04926467RecruitingPhase 2
Chemo plus anakinra for pancreatic cancer
This Phase 2 study tests whether adding anakinra (an immune signal blocker) to standard chemotherapy can improve outcomes for some people with pancreatic ductal adenocarcinoma. It’s mainly for adults with stage I–III disease who have enough organ function and are able to come in for treatment and follow-up.
Dallas, TexasAges 18 years+ - NCT07483554RecruitingPhase 2
IBI343 combination therapy for advanced solid tumors
This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT04704505RecruitingPhase 2
Testosterone-like treatment plus radium for bone-spread prostate cancer
This trial studies whether adding a testosterone-related therapy (BAT) to radium-223 can better control prostate cancer that has spread mainly to the bones. It may help shrink tumors in the bone and slow PSA rises, which are a common marker of prostate cancer activity.
Baltimore, MarylandAges 18 years+ - NCT06767800RecruitingPhase 2
Study of TQB2102 with immunotherapy for HER2-positive gastroesophageal cancer
This trial tests a new combination of drugs (TQB2102, benmelstobart, and pembrolizumab) with or without chemotherapy for people with HER2-positive gastroesophageal cancer that cannot be removed by surgery or has spread. It aims to see if this combination is more effective than current treatments.
Fuyang, AnhuiAges 18–75 - NCT07664891Recruiting
Metabolism and surroundings in pancreatic cancer
This study looks at how the metabolism of pancreatic cancer cells affects their surroundings. It uses a biopsy (removing a small sample of tissue from a tumor in the pancreas, liver, or lung) to learn more about the cancer and guide treatment.
MarseilleAges 18 years+ - NCT07044453RecruitingPhase 2/Phase 3
Extra chemo tailored to tumor stage for operated pancreatic cancer
This trial tests whether giving different types of extra chemo (after surgery) based on the stage of your cancer can help prevent it from coming back. It's for people with pancreatic cancer who already had chemo and surgery.
RouenAges 18 years+ - NCT06123494RecruitingPhase 3
A trial of SHR-A1811 for HER2-positive gastric cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06482788RecruitingPhase 2
Immunotherapy plus chemo before & after junction cancer surgery
This trial tests giving an immunotherapy drug (adebrelimab) along with two chemotherapy drugs (capecitabine and oxaliplatin) before and after surgery for a specific type of stomach-cancer junction tumor. It aims to see if this combination is safe and effective in shrinking the tumor and improving outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06892054RecruitingPhase 1
Targeted therapy plus chemo for advanced pancreatic cancer
This study tests a new targeted drug called sotorasib combined with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12C mutation. The goal is to see if the combination works better than chemotherapy alone.
Avignon, FranceAges 18 years+ - NCT07362186RecruitingPhase 3
LM-108 with Toripalimab vs Paclitaxel for advanced stomach cancer
This trial tests a new combination of two immunotherapy drugs (LM-108 and Toripalimab) against a standard chemotherapy drug (Paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CCR8. It may be an option if you have already tried a first-line therapy and your cancer has progressed or you had side effects from chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04989985RecruitingPhase 2
SOX chemotherapy plus immunotherapy for junction stomach-esophagus cancer
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
Guangzhou, GuangdongAges 18–75
Hear when a new Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adenocarcinoma?
- Yes. Clin2 currently lists 995 recruiting adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.